2 results
Approved WMOCompleted
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
Approved WMOCompleted
To assess the prevalence of subclinical AF in obesity patients by using different contemporary AF-detection applications (primary objective). To investigate the potential role of GLS as a parameter to predict presence of AF in obesity patients (…